Impact of thyroid immune-related adverse events on clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with checkpoint inhibitor therapy: A single center study. Biomol Biomed [Internet]. 2025 Mar. 24 [cited 2025 Apr. 2];. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/12321